Stock Report: EnteroMedics Inc. (ETRM) Report Updated: May 20, 2013 | Print This Page

EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company is developing Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, Norway, and Switzerland. It has collaborations with Mayo Clinic and Australian Institute of Weight Control for research and development of its products. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.